CD8 T-cells suppress resistance development to MAPK inhibitors in BRAF and NRAS-mutant melanoma with high mutational burden and targeting IPRES can enhance the anti-tumor activity of combined BRAF inhibitor and anti-PD-1 antibody. This evidence concerns the gene NRAS and melanoma.